A Randomized Phase II Trial Comparing a Calcineurin Inhibitor-Free Graft-Versus-Host Disease Prophylaxis Regimen with Post-Transplantation Cyclophosphamide and Abatacept to Standard of Care
- Resource Type
- Article
- Authors
- Koura, Divya; Tzachanis, Dimitrios; Ball, Edward D.; Costello, Caitlin; Goodman, Aaron M; Mangan, James K.; Mulroney, Carolyn; Maroge, Joseph; Padilla, Michelle; Breslin, Peggy; Garrett, Jodi; McConnell, Kimberly
- Source
- Blood; November 2021, Vol. 138 Issue: 1, Number 1 Supplement 1 p1816-1816, 1p
- Subject
- Language
- ISSN
- 00064971; 15280020
Background: Graft versus host disease (GVHD) is one the major causes of mortality and morbidity after an allogeneic stem cell transplantation. We hypothesized that we can induce post-transplant tolerance by using the combination of post-transplant cyclophosphamide (PTCy) and abatacept (CTLA4Ig) for GVHD prophylaxis. PTCy when given on Days +3 and +4 can eliminate host-reactive donor T cells. CTLA4Ig blocks the costimulatory signals given through CD28 to naïve donor T cells thus favoring an anergic phenotype that promotes tolerance towards recipient derived antigens. CTLA4Ig gives an activating signal to NK cells and therefore has the ability to preserve the graft-versus-tumor effect.